The Utility of PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men With High GC Decipherae Test Scores: A Sub-aim of the VANDAAM Study (MCC #18523)

What this Trial Is About

This research focuses on men with prostate cancer who previously participated in a study called VANDAAM and had high-risk Decipher test results indicating a high genomic classifier (GC) score. The study aims to evaluate the safety and usefulness of a new imaging method called F-DCFPyL Prostate-specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in detecting recurrent or metastatic prostate cancer. This imaging technique is not yet standard care but may improve how prostate cancer spread is identified and managed in the future. Participants will undergo F-DCFPyL PSMA PET imaging once a year for four years. Each imaging session involves receiving an injection of 9 b1 1 mCi of F-DCFPyL via a catheter placed in a vein. This radioactive diagnostic agent helps highlight cancer cells during the PET scan. The study includes men treated with surgery or radiation therapy at least two years prior and follows their imaging results over time. During the study, researchers will monitor the concordance between high tumor genomic risk scores and positive PSMA-PET imaging findings for up to five years. They will also track the rate of positive PSMA-PET results over this period. Participants' health is assessed with performance status evaluations, and the imaging is done annually. The total participation involves multiple annual imaging visits and follow-up evaluations to better understand the imaging test's value in detecting early metastatic prostate cancer.

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores